XU Bo, M.D., President of Chongqing University Cancer Hospital, Doctoral Supervisor Field of expertise: Oncology and Oncology Radiobiology Academic positions: Director of the Chinese Anti-Cancer Association, Overseas Fellow of the […]
XU Bo, M.D., President of Chongqing University Cancer Hospital,
Field of expertise: Oncology and Oncology Radiobiology
Academic positions: Director of the Chinese Anti-Cancer Association, Overseas Fellow of the Royal Medical Association, Chairman of the Chinese Anti-Cancer Association Tumor Artificial Intelligence Committee, Standing Committee Member of the Chinese Anti-Cancer Association Tumor Early Diagnosis and Treatment Committee
Dr. Bo Xu is President of CUCH, and he also serves as President of National Society of Artificial Intelligence in Oncology, China Anti-Cancer Association (CACA). His previous positions include Vice President of Tianjin Medical University Cancer Institute and Hospital, as well as Distinguished Fellow and Chairman of Oncology Department at Southern Research Institute (SRI) and Professor of Pathology at University of Alabama at Birmingham (UAB) in the United States, where he headed the long-standing cancer research program at SRI. Currently he also serves on the Board of Directors of CACA, an oversea fellow the Royal Society of Medicine of UK, and the editorial board of Radiotherapy and Oncology (the Green Journal) and the Biomedical Journal.
Dr. Xu received Ph.D. degree (1998) in Radiation Oncology from the Peking Union Medical College and he completed his postdoctoral training at St. Jude Children’s Research Hospital in Memphis, TN. In 2002, Dr. Xu started a faculty position at the LSU Health Sciences Center in New Orleans, serving as tenure-tracked Assistant Professor in the Department of Genetics. He joined SRI in 2006 as Associate Professor and Head of the Molecular Radiobiology Laboratory. Between 2009-2012, he had served as Professor and Director of Molecular Radiation Oncology in The Houston Methodist Hospital, Weill Cornell Medical College of Cornell University.
Dr. Xu’s major research interest is on molecular mechanisms of the DNA damage response. He has published more than 75 peer-review papers in major biomedical journals (including Nature, Cell, Molecular Cell), with more than 8000 citations. Six of his papers have been recommended by Faculty 1000.